Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT05653765
Active, not recruiting Observational

Prognostic Value of the AMR Measured After PPCI in STEMI Patients

NCT05653765 · tracked via the Priya Life Science China tracker
Sponsor
Henan Institute of Cardiovascular Epidemiology
Phase
Observational
Started
2022-12-20
Last updated
2025-03-17

Condition(s) studied

Coronary Heart DiseaseST Elevation Myocardial Infarction

Study summary

The goal of this observational study is to learn about in STEMI with Primary PCI Patients. The main questions it aims to answer are:

* To determine the value of AMR in predicting the long-term clinical prognosis of patients with STEMI after PPCI, and to find the best cut-off value.
* Analyze the factors of PPCI affecting AMR and explore the effective measures of PPCI microcirculation protection.

Radiographic images of STEMI receiving primary PCI treatment in several chest pain centers in China will be included. The last image of the infarct-related vessel will be used as a target to calculate its AMR. The relationship between AMR and long-term clinical prognosis was analyzed.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged 18 or older * Type 1 myocardial infarction * Receive PPCI Exclusion Criteria: * Failed to identify culprit vessels. * Structural heart disease with moderate to severe aortic valve or mitral regurgitation and or stenosis that may affect cardiac function * Dialysis patients with severe renal insufficiency * Severe and uncontrollable arrhythmia * Complicated with dilated cardiomyopathy * Unable to tolerate dual antiplatelet therapy * Severe and uncontrollable anemia * Hyperthyroidism * TIMI blood flow 0-1 grade after PPCI

Primary outcome measure(s)

  • MACEs — 12 months
    cardiac death, hospitalization for heart failure, target vessel revascularization，non-fatal MI

Trial sites (5)

FacilityCityRegionStatus
Shangqiu first people's Hospital Shangqiu Henan
Department of Cardiology, First Affiliated Hospital of Xinxiang Medical University Xinxiang Henan
Yongcheng Central Hospital Yongcheng Henan
Fuwai central China cardiovascular Hospital Zhengzhou Henan
Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Shanghai Municipality

More Henan Institute of Cardiovascular Epidemiology trials in China

Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension Starting soon
CRIC Combined With MFT for Cardiovascular Adverse Events in Patients With Incomplete Revascularization of CAD Recruiting
Influencing Factors and Outcomes of DCB Angioplasty Enrolling by invitation
Long-term Remote Ischemic Preconditioning Improves Myocardial Perfusion and Prognosis of Patients After CABG Recruiting
Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Mild Hypertension Recruiting

Other trials for the same condition

Inclisiran Effectiveness in China: a Pragmatic Randomized Trial Active, not recruiting
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction Recruiting
Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study ) Starting soon
Construction of a Prospective Cohort Database for the Perioperative Period of Cardiac Surgery Recruiting
Study of Sivelestat Sodium in OPCABG Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05653765 on ClinicalTrials.gov ↗ ← All trials in China